Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating

TIPRANKS01-10

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target of $3.00. Joseph Pantginis has...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602370165?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-10 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602370165","market":"fut","top_or_hot":-1,"title":"Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating","media":"TIPRANKS","content":"<div>\n<p>H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target of $3.00. Joseph Pantginis has...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-as-a-pivotal-year-for-tn-201-and-tn-401-clinical-readouts-and-regulatory-de-risking-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-10 00:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-as-a-pivotal-year-for-tn-201-and-tn-401-clinical-readouts-and-regulatory-de-risking-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target of $3.00. Joseph Pantginis has...</p>\n\n<a href=\"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-as-a-pivotal-year-for-tn-201-and-tn-401-clinical-readouts-and-regulatory-de-risking-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNYA","symbol_name":"Tenaya Therapeutics Inc","start_time":0,"source_url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-as-a-pivotal-year-for-tn-201-and-tn-401-clinical-readouts-and-regulatory-de-risking-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","article_id":"2602370165","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-as-a-pivotal-year-for-tn-201-and-tn-401-clinical-readouts-and-regulatory-de-risking-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602370165","pubTimestamp":1767975376,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target of $3.00. Joseph Pantginis has...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"TNYA":"Tenaya Therapeutics Inc"},"translate_title":"Tenaya Therapeutics：2026年是TN-201和TN-401临床读数和监管去风险的关键一年，支持买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNYA":1.5},"content_text":"H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target of $3.00. Joseph Pantginis has...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602370165","isCrawlerRequest":true}